stroke
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Experiment 1: (1) The patient met the diagnostic criteria for stroke determined by the Fourth National Conference on Cerebrovascular Diseases, and was confirmed by CT or MRI; (2) First, unilateral onset and stable disease; (3) Unilateral limb paralysis; (4) Aged 30-80 years; (5) The duration of the disease was less than 3 months; (6) FAC=20; (8) Family members and patients sign informed consent. 2. Experiment 2: (1) The patient met the diagnostic criteria for stroke determined by the Fourth National Conference on Cerebrovascular Diseases, and was confirmed by CT or MRI; (2) First, unilateral onset and stable disease; (3) Unilateral limb paralysis; (4) Aged 30-80 years; (5) The duration of the disease was less than 6 months; (6) FAC>=3, and can complete 10m walking under supervision; (7) Clear consciousness and cooperation, good cognition, MMSE>=20; (8) Family members and patients sign informed consent. 3. Experiment 3: (1) The patient met the diagnostic criteria for stroke determined by the Fourth National Conference on Cerebrovascular Diseases, and was confirmed by CT or MRI; (2) First, unilateral onset and stable disease; (3) Unilateral limb paralysis; (4) Aged 30-80 years; (5) The duration of the disease was less than 1 year; (6) Brunnstrom III-V stage of hemiplegic lower extremity; (7) Clear consciousness and cooperation, good cognition, MMSE>=17; (8) Family members and patients sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Experiment 1 and Experiment 2: (1) Infratentorial stroke; (2) Lower limb deformity or joint contracture, injury, lower limb movement restriction, pain; (3) Lower limb muscle tone improved ashworth>= grade 2; (4) Patients with cognitive and communication disorders cannot cooperate with treatment; (5) Patients with severe complications after stroke, such as serious heart disease, serious infection, and severe diabetes, are not suitable for this study; (6) Patients with hemiplegic side leg anaesthesia, skin injury, sensory allergy and irritation area intolerance. 2. Experiment 3: (1) Patients with progressive stroke or malignant progressive hypertension, serious visceral system diseases, malignant tumors, etc.; (2) Previous history of organic brain diseases, mental disorders, epilepsy; (3) Treat local skin injury, inflammation or hyperalgesia in stimulated areas; (4) Improved Ashworth score of the affected lower extremity >= grade 3; (5) Complicated diseases that seriously affect sensation and movement of lower limbs, such as rheumatoid arthritis, lumbar disc herniation, lower limb trauma, severe skin damage, fracture and peripheral neuropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional near infrared spectroscopy;Fugl-Meyer lower extremity function assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Berg balance scale;Modified Barthel index;Functional independence measurement (walking ability component);Mini-mental state examination; | — |
Countries
China
Contacts
Changzhou De'an Hospital; The People's Hospital of Jiangsu Province